Peptides in longevity and sports medicine – A practical GP Perspective

By Dr Niall Graham

Peptides have moved from underground bodybuilding forums into mainstream longevity and performance discussions. Patients are no longer just elite athletes. They are 18- to 80-year-old professionals training hard, recovering slower, wanting to stay metabolically sharp and injury free.

As a GP with an interest in both longevity and sports medicine, my role is not to hype them or dismiss them. It is to explain what they are, what the physiology suggests, what the evidence shows, and where the risks sit.

At their core, peptides are short chains of amino acids that act as signalling molecules.
They tell cells to do something:

• Repair tissue.
• Release growth hormone.
• Modulate inflammation.
• Influence mitochondrial function.
• They are messengers, not magic.

Some are well established in medicine. Many are not.
That distinction matters.

Body Protection Compound

Originally isolated from gastric juice, this peptide is discussed heavily for tendon, ligament, and gut repair.

Why it attracts attention:

• Animal data showing accelerated tendon healing
• Angiogenesis modulation
• Anti-inflammatory signalling

The issue:
There are no high quality human RCTs demonstrating clear efficacy in musculoskeletal injury. Most human data is anecdotal or uncontrolled.

That does not mean it does not work. It means the certainty is low.

Thymosin Beta 4 fragment

Involved in cellular migration and tissue remodelling. Often paired with BPC in what is commonly called a recovery stack.

Again, strong animal data. Sparse human clinical trial data. Off label use dominates discussion.

A fragment of the growth hormone molecule designed to stimulate lipolysis without affecting IGF 1 or glucose metabolism.

There is some human data in obesity trials. Results were modest. It is not a substitute for energy balance, resistance training, or sleep optimisation.

In longevity medicine, stacking refers to combining peptides that act on different pathways.

Recovery stack
BPC 157 plus TB 500
Goal: connective tissue repair and reduced inflammatory signalling.

Performance stack
CJC 1295 plus Ipamorelin
Goal: enhance endogenous GH release, improve sleep, support lean mass.

Longevity oriented stack
GHK Cu for collagen support
MOTS c for mitochondrial signalling

The theoretical biology is interesting. The human outcome data remains early.

As with any hormonal manipulation, more is not better. Physiology operates within ranges for a reason.

In Australia, many peptides are Schedule 4 and require prescription. Some are not approved for human therapeutic use. Sport Integrity Australia bans most growth hormone related agents.

Patients need to understand that “research use only” online vendors are not operating within Australian regulatory standards.

• Purity and sourcing
• Unregulated products may contain:
• Incorrect dosing
• Endotoxins
• Contaminants
• Completely different compounds

That is not theoretical. It is documented.

Manipulating GH, IGF 1, inflammatory signalling, or mitochondrial pathways is not benign.

Potential risks include:

• Insulin resistance
• Fluid retention
• Carpal tunnel-like symptoms
• Theoretical cancer signalling concerns with chronic GH elevation
• Unknown long-term effects
• Absence of long-term harm data is not the same as proof of safety.

Peptides are not first line therapy.

Before considering them, I look at:

• Sleep architecture
• Protein intake
• Resistance training stimulus
• Vitamin D
• Iron status
• Thyroid function
• Testosterone and SHBG if clinically indicated
• ApoB and metabolic risk
• Body composition trends

If those are not optimised, peptides are premature.

If someone is metabolically unhealthy, poorly sleeping, sedentary, and stressed, peptides will not fix that.

In a highly optimised individual with a persistent injury or genuine performance plateau, I understand why peptides enter the conversation. The biology is interesting, and I recognise that some patients will choose to explore that space. This is something I recognise and If that is the chosen path, I will do my best to ensure anyone who chooses this route is supported and all steps I can do are made to prioritise their health.

Longevity medicine is not about adding more compounds. It is about compressing morbidity and preserving function.

• Resistance training
• Zone 2 conditioning
• Metabolic health
• Inflammation control
• Sleep depth
• Cognitive load management

These remain foundational.

Peptides are tools.

Sometimes interesting tools. Occasionally useful tools. Not substitutes for physiology.

If you are considering them, the conversation should include:

• Clear goals
• Baseline biomarkers
• Regulatory awareness
• Risk discussion
• Defined review timeframes
• Optimisation without measurement is guesswork.
• And medicine without scepticism is marketing.

I genuinely love innovation in medicine. The peptide space is fascinating and, from a biological perspective, hugely exciting. The idea that we can influence recovery, tissue repair, metabolism, and cellular signalling with targeted molecules is at the very least exciting.

But excitement must sit alongside caution.

Promising science is not the same as long term human outcome data.

Mechanism is not the same as proof, and absence of evidence of harm is not the same as evidence of safety.

My role is to help patients navigate that middle ground, to give my view of the evidence and to support patients to make informed decisions, to explore new options thoughtfully, without abandoning fundamentals or ignoring risk.

It most certainly isn’t my place to judge, I’m always happy to have the discussion in a safe and non-judgemental space.

For most people, the biggest improvements in performance and longevity still come from:

• Consistent resistance training
• Cardiovascular fitness
• High quality sleep
• Adequate protein intake
• Metabolic health

Peptides may have a role in selected individuals. But they should sit on top of a solid foundation, not replace it.

I do not prescribe unapproved peptide therapies. However, I will have an open and honest discussion about them. That includes reviewing the available evidence, clarifying what is known and unknown, outlining regulatory and sporting implications in Australia, and discussing potential risks.

If a patient proceeds independently, my role remains to prioritise safety. I am willing to support appropriate monitoring, review biomarkers where clinically indicated, and ensure that decisions are made with informed consent and realistic expectations.

Transparency, safety, and clinical integrity need to be a priority, but there is no doubt, this is an exciting space, and a fascinating topic.